Immune checkpoint inhibitor
AssigneeRandox Laboratories Limited
InventorsMarshall Dunlop, Shirley Schon, John Lamont, Peter Fitzgerald
Life of this patent
Estimating the term…
Abstract
The present invention relates to therapeutic antibodies, or antigen-binding portions thereof, for use in the treatment of cancer and infectious disease. Specifically, the present invention relates to therapeutic antibodies, or antigen-binding portions thereof, that target the programmed death-ligand 1 polypeptide. The present invention also relates to pharmaceutical compositions comprising said therapeutic antibody, or antigen-binding portions thereof.
Claims16
An antibody or antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof has at least 80% sequence identity to SEQ ID NO:
- 7, and wherein the antibody or antigen-binding portion thereof can specifically bind a programmed death-ligand 1 (PD-L1) polypeptide, and wherein the antibody or antigen-binding portion thereof comprises one or more heavy chain CDRs, wherein (i) a heavy chain CDR1 has at least 70% sequence identity to SEQ ID NO:
- 1, (ii) a heavy chain CDR2 has at least 70% sequence identity to SEQ ID NO:
- 2 and (iii) a heavy chain CDR3 has at least 70% sequence identity to SEQ ID NO:
- 3.
3-8. (canceled)
Dependencies are inferred from the claim text.